A few medications under preliminary for COVID-19, remdesivir driving contender: Scientists Kumar Jeetendra | May 23, 2020 With an antibody still a significant distance away, endeavors to repurpose old drugs utilized for different illnesses give any expectation of an early counter to COVID-19, state researchers, setting the antiviral remdesivir on the rundown of potential contenders. As COVID-19 proceeds with its spread – crossing 5.2 million cases and 3,38,000 fatalities on Saturday – …
Maharashtra govt will acquire 10,000 vials of Remdesivir to treat COVID-19 patients: Tope Kumar Jeetendra | June 6, 2020 The Maharashtra government will acquire 10,000 vials of the medication Remdesivir for rewarding coronavirus patients, Public Health Minister Rajesh Tope said on Saturday. The costly medication is being made accessible for poor people and penniless patients in the state, he said. “GoM to obtain 10k vials of Remdesivir. In view of proof from research facility, …
Remdesivir eases back COVID-19 movement in macaques: Study Kumar Jeetendra | June 10, 2020 Washington, Jun 10 (PTI) Early treatment with the antiviral medication remdesivir has been found to diminish viral load and forestall lung sickness in macaques contaminated with SARS-CoV-2 that causes COVID-19, as indicated by an examination. The discoveries, distributed in the diary Nature on Tuesday, bolster the early utilization of remdesivir treatment in patients with COVID-19 …
India’s Zydus Cadila to make Gilead’s potential COVID-19 medication remdesivir Kumar Jeetendra | June 13, 2020 Indian drugmaker Zydus Cadila said on Friday it marked a non-selective permitting agreement with Gilead Sciences Inc to make and market antiviral medication remdesivir, the main treatment to show improvement in COVID-19 preliminaries. Zydus, recorded as Cadila Healthcare, joins other Indian pharmaceutical organizations Cipla Ltd, Jubilant Sciences Ltd and secretly held Hetero Labs Ltd in …
Hetero, Cipla get gesture to make, market antiviral medication remdesivir Kumar Jeetendra | June 21, 2020 India’s Drug Regulator on June 20 allowed to Hetero and Cipla to produce and market antiviral medication remdesivir for “confined crisis use” on hospitalized COVID-19 patients, official sources said. This comes a day after the Drug Controller General of India (DCGI), thinking about the crisis and neglected requirement for medications considering the coronavirus episode, allowed …
Cipla launches Cipremi:remdesivir lyophilised powder for injection 100 mg Kumar Jeetendra | June 21, 2020 Cipla Limited (BSE: 500087; NSE: CIPLA EQ, hereinafter referred to as “Cipla”), today announced the launch of remdesivir under its brand name CIPREMI. The U.S. FDA issued an Emergency Use Authorization (EUA) to Gilead Sciences Inc. for emergency use of remdesivir for the treatment of hospitalized 2019 coronavirus disease (COVID-19) patients. It is the only …
Cipla dispatches nonexclusive rendition of remdesivir in India Kumar Jeetendra | July 9, 2020 Pharma important Cipla on Wednesday said it has launched its own generic version of antiviral drug remdesivir at a cost which is one of the lowest internationally and is seeking to supply over 80,000 vials over the first month. The company, however, did not disclose the purchase price of the medicine. Cipla had earlier said …
Jubilant Life Sciences presents 1,000 vials of Remdesivir to Uttar Pradesh CM Yogi Adityanath Kumar Jeetendra | August 8, 2020 Drug firm Jubilant Life Sciences on Saturday said it has introduced 1,000 vials of antiviral drug Remdesivir that it sells under the brand name’JUBI-R’ into Uttar Pradesh Chief Minister Yogi Adityanath. The drug has been made accessible to over 1,000 hospitals supplying COVID-19 treatment in India throughout the organization’s distribution system, Jubilant Life Sciences said …
Cipla scales up assembling of remdesivir to fulfill high need Kumar Jeetendra | August 11, 2020 Medicine manufacturer Cipla said on Tuesday it is rising up the production of antiviral drug remdesivir, used in COVID-19 treatment, by manufacturing the drug at its Goa plant. “Presently the requirement is enormous for remdesivir, also we’re scaling up our internal production of Remdesivir,” Kedar Upadhye, global chief financial officer of Cipla, told Moneycontrol. Upadhye …
WHO-drove COVID-19 medication plot copies down on antibodies, steroids and disregards remdesivir Kumar Jeetendra | November 6, 2020 A World Health Organization-led scheme to provide COVID-19 drugs to poor countries is gambling on experimental monoclonal antibody treatments and steroids but is shunning Gilead’s remdesivir blockbuster therapy, an internal document shows. The WHO draft document, seen by Reuters and dated October 30, states the priorities are to secure monoclonal antibodies in a tight market …
